Table 1.
Demographic and clinical characteristics.
| Variable | n (%) |
|---|---|
| Gender | |
| Male | 70 (71.4%) |
| Female | 28 (28.6%) |
| Employment status | |
| 3rd level education | 8 (8.2) |
| Employed | 26 (26.5) |
| Unemployed | 64 (65.3) |
| Relationship status | |
| Single | 79 (80.6) |
| In a relationship | 4 (4.1) |
| Married | 12 (12.2) |
| Divorced / separated | 3 (3.1) |
| Living arrangements | |
| Alone | 25 (25.2) |
| With parents or siblings | 39 (39.8) |
| With partner or spouse | 13 (13.3) |
| In supported accommodation* | 21 (21.4) |
| Socioeconomic class | |
| I or II | 10 (10.2) |
| III | 21 (21.4) |
| IV | 8 (8.2) |
| V | 59 (60.2) |
| Diagnosis | |
| Schizophrenia | 89 (90.8) |
| Schizoaffective disorder | 9 (9.2) |
| Additional antipsychotic agents | |
| Amisulpride | 12 (12.2) |
| Aripiprazole | 14 (14.3) |
| Olanzapine | 3 (3.1) |
| Risperidone | 1 (1.0) |
| Haloperidol | 1 (1.0) |
| Flupenthixol decanoate | 1 (1.0) |
| Zuclopenthixol decanoate | 1 (1.0) |
| None | 65 (66.3) |
| Mood stabiliser medications** | |
| Sodium valproate | 12 (12.2) |
| Lamotrigine | 6 (6.1) |
| Lithium | 5 (5.1) |
| None | 77 (78.6) |
| Antidepressants | |
| Yes | 18 (18.4) |
| No | 80 (81.6) |
| Treatments utilized to reduce hypersalivation | |
| Hyoscine hydrobromide | 13 (13.3) |
| Scopolamine patch | 2 (2.0) |
| Pirenzipine | 1 (1.0) |
| Procyclidine | 1 (1.0) |
| None | 81 (82.7) |
| Mean (SD), range | |
| Age | 41.4 (12.1), 18–83 |
| Clozapine treatment | |
| Dose (mg/day) | 354.1 (159.4), 75–925 |
| Serum level | 0.41 (0.24), 0.1–1.4 |
| Duration of treatment (years) | 7.3 (6.7), 0.2–21.5 |
*
Accommodation provided by mental health or homeless services.
**
Two participants were on two mood-stabilizing medications.